MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.64
+0.41 (3.65%)
At close: Sep 4, 2026, 4:00 PM EDT
11.41
-0.23 (-1.98%)
After-hours: Sep 4, 2026, 7:30 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 15 employees as of December 31, 2025. The number of employees decreased by 8 or -34.78% compared to the previous year.
Employees
15
Change (1Y)
-8
Growth (1Y)
-34.78%
Revenue / Employee
n/a
Profits / Employee
-$757,359
Market Cap
59.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | -8 | -34.78% |
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Celularity | 115 |
| Alps Group | 93 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| Seres Therapeutics | 66 |
| eXoZymes | 32 |
| ImageneBio | 18 |
INKT News
- 23 days ago - MiNK Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - MiNK Therapeutics Earnings release: Q2 2026 - Filings
- 23 days ago - MiNK Therapeutics Quarterly report: Q2 2026 - Filings
- 23 days ago - MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial - TheFly
- 4 weeks ago - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire